Pre-seed · Raised $2.8M · Jul 22, 2026announcement ↗
Immitra Bio
Backed by
BiotechZürich, Switzerlandimmitrabio.com ↗
What they do
Immitra Bio is an ETH Zürich spin-off developing in-vivo gene-editing and stem-cell therapies for rare genetic diseases. Its platform aims to use a single, off-the-shelf injection to treat severe inherited blood disorders without chemotherapy or cell transplantation, initially focusing on preclinical disease-reversal studies.
Hiring outlook
With CHF 2.4 million in pre-seed funding, the company is likely to prioritize founding or early hires in gene editing, stem-cell biology, translational research, and preclinical development. It may also add limited computational biology or platform-engineering support for its target-identification technology.
Open roles
Pre-flood window open
Nothing posted yet since the raise, which is exactly when a direct, well-aimed email to a founder beats every job portal. When the postings go up, so does the competition.
Get founders like this to reach you →